Skip to main content

Table 4 Changes in NEI-VFQ-25 subscale scores from baseline to 3 months in each baseline vision group (N=98)

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

NEI VFQ-25 Subscale

Decimal visual acuity

Below 0.5

Above 0.6

CFB

95%CI

P value

CFB

95%CI

P value

Lower

Upper

Lower

Upper

Overall

5.1

2.7

7.5

0.00004

3.8

1.0

6.6

0.00729

General health

1.3

−3.5

6.2

0.58639

1.3

−4.4

7.0

0.65704

General vision

9.9

5.3

14.6

0.00005

9.2

3.8

14.7

0.00106

Ocular pain

1.1

−2.4

4.7

0.5226

2.9

−1.2

7.0

0.16917

Near activities

8.0

3.2

12.8

0.00123

7.8

2.3

13.3

0.00589

Distance activities

3.0

−0.9

6.8

0.12973

1.6

−2.9

6.1

0.4826

Social functioning

4.3

0.5

8.2

0.02752

3.5

−0.9

8.0

0.12142

Mental health

10.4

6.0

14.7

0.00001

4.5

−0.6

9.6

0.08608

Role difficulties

5.6

0.3

11.0

0.04003

5.4

−0.8

11.7

0.08844

Dependency

5.3

1.2

9.3

0.01196

3.8

−0.9

8.6

0.11354

Driving

−2.2

−8.8

4.4

0.50748

−1.5

−8.2

5.2

0.65724

Color vision

0.8

−3.3

5.0

0.69179

−0.3

−5.1

4.5

0.9098

Peripheral vision

5.5

−0.3

11.3

0.0639

1.8

−4.9

8.4

0.5975

  1. CFB Change from baseline, CI confidence interval, NEI-VFQ-25 25-item National Eye Institute Visual Function Questionnaire